Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...
Tectonic Therapeutic reports ‘positive’ data from Phase 1b trial for TX45
Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...
Tectonic Therapeutic Shares Hit 52-Week High After Positive Trial Data
Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...
Tectonic Therapeutic stock soars on positive trial data
The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Le Lézard10h
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIRtm (sotatercept-csrk) Early and Move to Final Analysis
Merck , known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background ...